Dynamics of quality of life indicators in patients with gastroesophageal reflux disease comorbid with connective tissue dysplasia under the influence of complex treatment

Iryna B. Romash, Ivan R. Romash
Ivano-Frankivsk National Medical University, Ukraine.

Abstract

Introduction. In the case of gastroesophageal reflux disease (GERD) on the background of undifferentiated connective tissue dysplasia (UCTD) causes an even more significant deterioration in the QOL, including sleep disturbances and the onset of excessive daytime sleepiness (EDS). Thus, the study of the peculiarities of GERD on the background of connective tissue dysplasia and determining the impact of comorbid pathology on the QOL of patients with GERD is a topical issue in internal medicine. It has significant socio-economic significance. We believe that monitoring the most important variables that affect the quality of life of patients with GERD can help raise public awareness in this regard. In addition, it can guide the healthcare system to address these issues.

Purpose. The purpose of the work is to increase the awareness of medical workers about the scale of the problem and ways to solve it. to study the features of the dynamics of quality of life in patients with gastroesophageal reflux disease comorbid with connective tissue dysplasia under the influence of the proposed complex therapy.

Methodology. 120 patients were included: 65 men and 55 women. In 75 of them (Study Group) GERD was in the background of UCTD, in 45 (Comparison Group) - developed as an independent disease. The Study Group was divided into three groups. Comparison Group - 45 patients with GERD without UCTD, received basic standard therapy, which included PPI "Panocid" 40 mg once a day and alginate-antacid formulation (Gaviscon Double Action Liquid) 20 ml. 3 times per day after meals and before bedtime. I Group - 25 patients with GERD + UCTD, which to the standard basic therapy was added "Magne-B6" for 2 tablets 3 times per day. II Group - 25 patients with GERD + UCTD, which to the standard basic therapy was added "Calcium-D3 Nicomed" 1 tablet 3 times per day. III Group - 25 patients with GERD + UCTD, who used the drug "Magne-B6" 2 tablets 3 times per day and "Calcium-D3 Nicomed" 1 tablet 3 times per day on the background of standard basic therapy. The Medical Outcomes Study 36-Item Short-Form Health Status (SF-36), the Gastrointestinal Symptom Rating Scale (GSRS), and the scale of "Personal and social performance" (PSP) - were used to study patients in detail. A comprehensive examination of patients was performed twice: before and after 30 days of comprehensive treatment.

Results and Discussion. Under the influence of the basic therapy in Comparison Group the General Health (GH) improved by 33.03%. While in the groups on the background of complex treatment is increased by 42.52% in patients of the I Group, by 13.10% in patients of the II Group, and 46.28% in patients of the III Group (p1, p2, p3 <0.05). Physical Functioning Scale (PF) improved by 17.9% in patients of the Comparison Group (p <0.05) and by 30.38%, 27.47%, 29.17%, respectively (p1, p2, p3 <0.05). Role Physical Scale (RP) scores improved by 25.14% in Comparison Group (p <0.05) and by 33.9%, 22.58% and 40.20% respectively (p1, p2, p3 <0.05). Dynamics of data in Body Pain (BP) scale improved by 21.84% in patients of the Comparison Group (p <0.05) and by 37.28%, 25.46%, 35.92% (p1, p2, p3 <0.05). As can be seen from it, under the influence of complex therapy, the values of the Vitality (VT) increased by 17.18% in patients of Group I, by 21.93% – in Group II, by 37.87% – in Group III (p1, p2, p3 <0.05). Among
patients of the Comparison Group, the influx of strength and energy felt 9.50% (p < 0.05). Data of Social Functioning Scale (SF) improved by 8.8% in patients of the Comparison Group (p < 0.05) and by 22.7%, 29.6%, 29.31%, respectively (p1, p2, p3 < 0.05). Mental Health Scale (MH) improved by 17.23% in patients of Group I, by 22.41% – in Group II, by 21.96% – in Group III (p1, p2, p3 < 0.05) and 14.22% - in the Comparison Group (p < 0.05). Also in patients were positive dynamics of the Role Emotional functioning scale (RE): by 27.37% in patients of Group I, by 12.36% – in Group II, by 15.7% – in the Group III (p1, p2, p3 < 0.05) and 9.05% - in patients of the Comparison Group (p < 0.05).

Conclusions. Thus, the inclusion in the standard therapy of gastroesophageal reflux disease in patients with its development on the background of undifferentiated connective tissue dysplasia of magnesium lactate dihydrate in combination with pyridoxine hydrochloride ("Magne-B6") and calcium carbonate in combination with cholecalciferol ("Calcium-D3 Nicomed") contributed to a significant improvement in their quality of life.

Keywords
quality of life, gastroesophageal reflux disease, comorbidity, connective tissue dysplasia, complex treatment.

Introduction
The problem of comorbid pathology in the patient XXI century becomes the rule rather than the exception. It causes significant costs for the diagnosis and treatment of such patients, and ultimately high disability and mortality.

Epidemiological studies in recent years have shown that gastroesophageal reflux disease (GERD) occupies a leading position among other acid-dependent gastrointestinal diseases and is a significant factor in health care costs. Depending on the study population, its prevalence is in the range of 10-30% and tends to increase (Charles Hill et al. 2020). Over the past 40 years, the incidence of GERD has increased significantly and has become one of the main clinical problems in gastroenterology. In North America, it is noted in 18.1-27.8%, in Europe - in 2.5-7.8%, in the Middle East - in 8.7-33.2% of cases. GERD is also increasingly found in Asians, where its prevalence averages about 8%.

According to research by Gorczyca R et al. (2019) and Ludici M e t. al. (2017) already in patients with GERD without concomitant pathology, the quality of life deteriorates due to functional limitations, emotional disorders, increased frequency of reflux. Patients with GERD usually suffer from a variety of symptoms, including acid regurgitation, epigastralgia, non-cardiac chest pain, chronic cough, asthma. Symptoms of nocturnal acid regurgitation may interfere with sleep. Therefore, patients with GERD may experience a loss of quality of life (QOL) much more often than the general population. (Salome Satya Vanii P et al., 2018). And this in turn affects the ability of people to perform daily activities, which closely affects the state of their well-being.

The urgency of the problem of GERD in addition to a serious impact on QOL and social functioning is the development of dangerous to the health
and life of patients complications: esophageal stricture, peptic ulcer, Barrett's esophagus, adenocarcinoma. Therefore, early diagnosis of the underlying disease and comorbid conditions is important to prevent the above complications. By the way, digestive disorders are increasingly recognized as one of the leading causes of disability worldwide. In 2019, these diseases took third place after cardiovascular and cancer diseases.

In the case of GERD on the background of undifferentiated connective tissue dysplasia (UCTD) causes an even more significant deterioration in the QOL, including sleep disturbances and the onset of excessive daytime sleepiness (EDS). This dependence is indicated by our previous correlation analysis and the establishment of a direct close relationship between the indicator of pathological acidification of the esophagus (acid exposure time - AET) and EDS in both groups. In our previous study, we found a significant decrease in QOL and social functioning (Romash, 2019, 2020). In particular, patients with a combination of GERD and UCTD significantly more often worried about heartburn, impaired quality of sleep, and life on 1.4 times (p <0.05). They increased the frequency of gastrointestinal reflux with pH <4, increased the number of acid reflux in the supine and standing positions.

Thus, the study of the peculiarities of GERD on the background of connective tissue dysplasia and determining the impact of comorbid pathology on the QOL of patients with GERD is a topical issue in internal medicine. It has significant socio-economic significance.

We believe that monitoring the most important variables that affect the quality of life of patients with GERD can help raise public awareness in this regard. In addition, it can guide the health care system to address these issues.

**Purpose**

The purpose of the work is to increase the awareness of medical workers about the scale of the problem and ways to solve it. To study the features of the dynamics of quality of life in patients with gastroesophageal reflux disease comorbid with connective tissue dysplasia under the influence of the proposed complex therapy.

**Design/Methodology/Approach**

120 patients have included 65 men and 55 women. In 75 of them (Study Group) GERD was in the background of UCTD, in 45 (Comparison Group) - developed as an independent disease. Depending on the treatment regimen, the experimental group was divided into three.

Comparison Group consisted of 45 patients with GERD without connective tissue disorders, who received basic standard therapy, which included PPI "Panocid" and alginate-antacid formulation (Gaviscon Double Action Liquid) 20 ml 3 times per day after meals and before bedtime.

I Group consisted of 25 patients with GERD in combination with UCTD, which was added to the basic therapy "Magne-B6" for 2 tablets 3 times per day.

I Group consisted of 25 patients with GERD on the background of UCTD, which was added to the basic therapy "Calcium-D3 Nicomed" 1 tablet 3 times per day.

III Group consisted of 25 patients with GERD in combination with UCTD, which was added to the basic therapy "Magne-B6" in 2 tablets. 3 times per day and "Calcium-D3 Nicomed" 1 tablet 3 times per day.

The Medical Outcomes Study 36-Item Short-Form Health Status (SF-36), the Gastrointestinal Symptom Rating Scale (GSRS), and the scale of "Personal and social performance" (PSP) - were used to study patients in detail.

A comprehensive examination of patients was performed twice: before and after 30 days of comprehensive treatment.

The sample of patients was representative by age and gender (Table 1).

| Indexes | Comparison Group (n=45) | I (n=25) | III (n=25) | III (n=25) |
|---------|-------------------------|--------|-----------|-----------|
| Age     | 46.2±3.03               | 36.2±3.03 | 32.2±3.03 | 29.2±3.03 |
After reviewing the examination procedure and
the principle of treatment, all patients voluntarily
signed written agreements following the protocol
of the clinical trial approved by the Bioethics
Commission of Ivano-Frankivsk National Medical
University. To assess the dynamics of quality of life
(QOL) of the examined patients under the
influence of complex treatment, each patient was
asked to fill out a short form of the questionnaire
Medical Outcomes Study 36-Item Short-Form
Health Status (SF-36) Ware et al. (1993) and the
Gastrointestinal Symptom Rating Scale (Svedlund
J, Dimenäs E, Wiklund I, 1995).

The SF-36 questionnaire consists of 36 questions
grouped into eight domains: physical functioning
(PF), social functioning (SF), role limitation related
to physical problems (RP), role limitation, gender
associated with emotional problems (RE), mental
health (MH), vitality (VT), body pain (VP) and
perception of general health (GH). The indicators
of each scale are compiled as follo
w: the higher
the value of the indicator (from 0 to 100), the better
the score on the selected scale. They form two
tempers that evaluate the eight concepts of
health: psychological and physical components.
The physical components are: GH - general
perception of health, PF - limitations in physical
activity due to health problems, RP - limitations in
normal role-playing activities due to physical
health problems, BP - physical pain. Mental
components include: SF - limitations in social
activity due to physical or emotional problems, MH
- general mental health (psychological distress
and well-being, RE - limitations in normal role
activity due to emotional problems, VT - viability
(energy and fatigue) The scores of each scale vary
between 0 and 100, where 100 is a completely
healthy, and the results are in the form of scores
compiled in such a way that a higher score
indicates a higher QOL level. The general
questionnaire is a general questionnaire that can
be used for patients with various pathologies as
well as for population-based studies. Of 15
questions grouped into five clusters for a detailed
study of symptoms reflecting reflux, abdominal
pain, indigestion, diarrhea, and constipation. GSRS
has a seven-point Likert-type scale, where "1"
means no problem symptoms and "7" means no
very problematic symptoms. The reliability and
validity of this questionnaire are well documented,
the values of the norms for the general population
are available (Kulich et.al., 2008).

Results and Discussion

The dynamics of the physical components of
quality of life under the influence of the proposed
comprehensive treatment in our examined
patients is presented in Figure 1.

Under the influence of the basic therapy
among the patients of the Comparison Group the
General Health (GH) improved by 33.03%,
changing from 52.81 ± 0.98 to 78.86 ± 1.03 ( p
<0.05). While in the groups on the background of
complex treatment it increased by 42.52% (from
54.3 ± 0.97 to 94.5 ± 1.97) in patients of the first
group, by 13.10% (from 62 .01 ± 1.87 to 71.36 ±
0.61) – in II and 46.28% (from 50.81 ± 1.07 to 94.6
± 2.01) – in the III, respectively (p1 , p2, p3 <0.05).
Fig. 1. Dynamics of quality of life indicators (physical component) in the examined patients

Note: * - (p < 0.05) data are reliable for indicators before and after treatment.

Physical Functioning Scale (PF) improved by 17.9% under the influence of the prescribed treatment (from 59.32 ± 0.97 to 72.3 ± 0, 61) in patients of the Comparison Group (p < 0.05) and by 30.38% (from 61.12 ± 1.38 to 87.8 ± 2.09) – in the I Group; 27.47% (from 57.01 ± 2.63 to 79.03 ± 0.97) – in the II Group; 29.17% (from 61.12 ± 0.68 to 86.3 ± 1.16) – in the III Group, respectively (p1, p2, p3 < 0.05).

Role Physical Scale (RP) scores improved by 25.14% (from 58.31 ± 0.91 to 77.9 ± 1.12) in Comparison Group (p <0.05) and by 33.6% (from 61.24 ± 1.12 to 92.3 ± 2.07) in patients of the I Group, by 22.58% (from 53.71 ± 0.76 to 69.38 ± 1.56) - in the II Group, by 40.20% (from 53.20 ± 0.13 to 89.12 ± 0.97) – in the III (p1, p2, p3 <0.05)

Dynamics of data in Body Pain (BP) scale under the influence of the proposed therapy improved by 21.84% (from 61.9 ± 0.89 to 79.2 ± 1.33) in patients of the Comparison Group (p < 0.05) and by 37.28% (from 59.2 ± 0.86 to 94.4 ± 1.25) – in the I Group, by 25.46% (from 58.36 ± 1.15 to 78.3 ± 2.13) – in the II Group, by 35.92% (from 59.41 ± 1.08 to 92.73 ± 1.05) – in the III Group (p1, p2, p3 <0.05).

Dynamics of mental components of quality of life under the influence of the offered complex treatment at the patients examined by us is presented in figure 2.
Fig. 2. Dynamics of quality of life indicators (mental component) in the examined patients

Notes: 1. * - (p <0.05) data are reliable in relation to indicators before and after treatment.

Under the influence of complex therapy, the values of the Vitality (VT) increased by 17.18% (from 72.3 ± 1.62 to 87.3 ± 0.97) in patients of Group I, by 21.93% (from 69.76 ± 1.32 to 89.36 ± 1.36) – in the Group II, in which the basic therapy was added to the calcium drug; by 37.87% (from 59.86 ± 0.96 to 96.36 ± 2.31) – in the Group III, to which both drugs were added to the basic therapy (p1, p2, p3 <0.05). Among patients with GERD without UCTD, who received basic therapy with PPIs and alginate-antacid formulation, the influx of strength and energy felt 9.50% (69.86 ± 0.32 to 77.2 ± 1.08), p <0.05.

Data of Social Functioning Scale (SF) under the influence of the proposed therapy improved by 8.8% (from 74.36 ± 0.98 to 81.5 ± 1.64) in patients of the Comparison Group (p <0.05) and by 22.7% (from 61.12 ± 0.81 to 79.1 ± 0.62) in patients in the Group I, by 29.6% (from 59.36 ± 1.65 to 84.3 ± 1.31) – in the Group II, by 29.31% (from 63.16 ± 0.38 to 89.36 ± 1.13) - in the Group III (p1, p2, p3 <0.05).

Mental Health Scale (MH) improved by 17.23% (from 71.26 ± 0.36 to 86.1 ± 1.95) in patients of the Group I, by 22.41% (from 61.96 ± 0.68 to...
79.86 ± 1.07) – in the Group II, 21.96% [from 79.19 ± 1.02 to 79.63 ± 2.03] – in the Group III [p1, p2, p3 <0.05] and 14.22% [from 68.36 ± 0.35 to 79.7 ± 1.04] - in the Comparison Group [p <0.05].

Also in the patients we treated there was a positive dynamics of the scale Role Emotional functioning (RE): by 27.37% (from 70.3 ± 1.16 to 96.8 ± 2.07) in patients of the Group I, by 12.36% (from 73.26 ± 0.64 to 83.6 ± 1.35) – in the Group II, by 15.7% (from 79.43 ± 0.38 to 94.3 ± 0.92) – in the Group III [p1, p2, p3 <0.05] and 9.05% (from 69.3 ± 0.31 to 76.2 ± 0.82) - in patients of the Comparison Group who received basic therapy [p < 0.05].

Conclusions

Thus, the inclusion in the standard therapy of gastroesophageal reflux disease in patients with its development on the background of undifferentiated connective tissue dysplasia of magnesium lactate dihydrate in combination with pyridoxine hydrochloride (“Magnesium -B6”) and calcium carbonate in combination with cholecalciferol (“Calcium-D3 Nicomed”) contributed to a significant improvement in their quality of life.

Conflict of interest

The authors declare that they have no conflict of interest.

References

Alshammari, S. A., Alabdulkareem, A. M., Aloqeely, K. M., Alhumud, M. I., Alghufaily, S. A., Al-Dossare, Y. I., & Alrashdan, N. O.. (2020). The Determinants of the Quality of Life of Gastroesophageal Reflux Disease Patients Attending King Saud University Medical City. Cureus. https://doi.org/10.7759/cureus.9505

Gorczyca, R., Pardak, P., Pełkala, A., & Filip, R.. (2019). Impact of gastroesophageal reflux disease on the quality of life of Polish patients. World Journal of Clinical Cases, 7(12), 1421–1429. https://doi.org/10.12998/wjcc.v7i12.1421

Hill, C., Versluijs, Y., Furay, E., Reese-White, D., Holan, C., Alexander, J., Doggett, S., Ring, D., & Buckley, F. P.. (2020). Psychoemotional factors and their influence on the quality of life in patients with GERD. Surgical Endoscopy. https://doi.org/10.1007/s00464-020-08145-8

Iudici, M., Irace, R., Riccardi, A., Cuorno, G., Vettori, S., & Valentini, G.. (2017). Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases. Patient Related Outcome Measures, Volume 8, 7–13. https://doi.org/10.2147/prom.s117767

Kulich, K. R., Madisch, A., Pacini, F., Piqué, J. M., Regula, J., Van Rensburg, C. J., Újszászy, L., Carlsson, J., Halling, K., & Wiklund, I. K.. (2008). Reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaire in dyspepsia: A six-country study. Health and Quality of Life Outcomes, 6(1), 12. https://doi.org/10.1186/1477-7525-6-12

Romash, I., Mishchuk, V. (2019). Improvement of Magnesium and Calcium Deficiency in Patients with Gastroesophageal Reflux Disease Associated with Undifferentiated Connective Tissue Disease. Galician Medical Journal, 26(4). https://doi.org/10.21802/gmj.2019.4.3

Romash, I. (2020). Disorders of social functioning and quality of life in patients with gastroesophageal reflux disease while combined with undifferentiated connective tissue dysplasia. Mental Health: Global Challenges Journal, 3(1), 11–16. https://doi.org/10.32437/mhgcj.v3i1.100

Romash, I.R., Vynnyk, M.I. (2020). Dynamics of Quality of Life Indices in Case of Metabolic Syndrome in Patients with Paranoid Schizophrenia on the Background of Atypical Neuroleptic Agents Application and Improvement of Comorbidity. Ukrain's'kyi visnyk psikhonevrolohi. 27, 4 (101):62-67. doi: https://doi.org/10.36927/2079-0325-V27-is4-2019-11

Salome Satya Vani P et al., (2018). Assessment on Patients Health Related Quality of Life Associated With Gerd. Int J Recent Sci Res. 9(4), pp. 25840-25845. DOI: http://dx.doi.org/10.24327/ijrsrc.2018.0904.1940

Yannasaki, T., Quan, S. F., & Fass, R. (2019). The effect of sleep deficiency on esophageal acid exposure of healthy controls and patients with gastroesophageal reflux disease. Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society, 31(12), e13705. https://doi.org/10.1111/nmo.13705